MYGN

Myriad Genetics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth 0/10
  • Momentum 1/10
Myriad Genetics sales and earnings growth
MYGN Growth
Low
  • Revenue Y/Y 0.21%
  • EPS Y/Y -238.28%
  • FCF Y/Y 72.51%
Myriad Genetics gross and profit margin trends
MYGN Profitability
Fair
  • Gross margin 70.40%
  • EPS margin -48.50%
  • ROIC -111.80%
Myriad Genetics net debt vs free cash flow
MYGN Risk
Great
  • Debt / Equity 0.6
  • Debt / FCF 2.3
  • Interest coverage -61.5

Myriad Genetics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Diagnostics & Research stocks ↗